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Abstract
The synthesis of purine conjugates with natural amino acids is one of the promising directions in search for novel therapeutic 
agents, including antimycobacterial agents. The purpose of this study was to synthesize N-(purin-6-yl)dipeptides contain-
ing the terminal fragment of (S)-glutamic acid. To obtain the target compounds, two synthetic routes were tested. The first 
of them is based on coupling of N-(purin-6-yl)-(S)-amino acids to dimethyl (S)-glutamate in the presence of carbodiimide 
coupling agent followed by the removal of ester groups. However, it turned out that this coupling process was accompanied 
by racemization of the chiral center of N-(purin-6-yl)-α-amino acids and in all cases led to mixtures of (S,S)- and (R,S)-
diastereomers (6:4). Individual (S,S)-diastereomers were obtained using an alternative approach based on the nucleophilic 
substitution of chlorine in 6-chloropurine or 2-amino-6-chloropurine with corresponding dipeptides as nucleophiles. The 
enantiomeric purity of the target compounds was confirmed by chiral HPLC. To test the assumption that racemization of 
the chiral center of N-(purin-6-yl)-α-amino acids occurs with the participation of nitrogen atoms of the imidazole ring via 
the stage of formation of a chirally labile intermediate, we obtained such structural analogs of N-(purin-6-yl)-(S)-alanine as 
N-(9-benzylpurin-6-yl)-(S)-alanine and N-(7-deazapurin-6-yl)-(S)-alanine. It was found that coupling of these compounds 
to dimethyl (S)-glutamate was also accompanied by racemization. This indicates that the imidazole fragment does not play a 
crucial role in this process. When testing the antimycobacterial activity of some of the obtained compounds, conjugates with 
moderate activity against the laboratory Mycobacterium tuberculosis H37Rv strain (MIC 3.1–6.25 μg/mL) were identified.
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Introduction
The synthesis of purine conjugates with natural amino acids 
is one of the promising directions in search for novel effi-
cient therapeutic agents. These compounds are known to 
be highly active against herpes viruses (Beauchamp et al. 
1992; Krasnov et al. 2019), HIV (McGuigan et al. 2005, 
2006), hepatitis C (McGuigan et al. 2010; Chang et al. 2011; 
Al-Harbi and Abdel-Rahman 2012), and influenza viruses 
(Pautus et al. 2013). It was also reported about purinyl amino 
acids exhibiting antitumor (Ward et al. 1961), antimycobac-
terial (Voynikov et al. 2014; Stavrakov et. al. 2016; Gru-
zdev et al. 2017, 2018; Krasnov et al. 2016, 2020), and other 
effects.
The modification of purine core at position N9 leading 
to the analogs of natural nucleosides has been widely used 
(Wang et al. 2015; Mehellou 2016). At the same time, the 
synthesis of C6-substituted derivatives is also an important 
area of the purine chemistry (Legraverend and Grierson 
2006; Legraverend 2008). The most common synthetic route 
to purine conjugates bearing an amino acid fragment at posi-
tion C6 is the nucleophilic substitution of the chlorine atom 
in 6-chloropurine (Ward et al. 1961; Niu et al. 2012; Boer-
ema et al. 2016). Depending on the chosen synthetic strat-
egy, reaction conditions and the amino acid structure, the 
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target compounds may be obtained in enantiomerically pure 
form or as a mixture of enantiomers (Vigorov et al. 2014).
The search for novel antimycobacterial agents is an urgent 
task. According to the World Health Organization, tubercu-
losis (TB) was diagnosed in 10 million people worldwide 
and 1.5 million people died of TB in 2018 (WHO 2019). 
Moreover, at present during the COVID-19 pandemic, there 
is an increased risk for unfavorable outcome in TB patients 
(Motta et al. 2020; WHO 2020). TB treatment is often com-
plicated because of the emergence of mycobacterium strains 
resistant to clinically used anti-TB drugs such as isoniazid 
and rifampicin (Tripathi et al. 2005; de Wet et al. 2019). 
Design of novel antimycobacterial agents differing in the 
mechanism of action from known drugs may be the solution 
to the problem of multidrug resistance (MDR).
To identify highly effective anti-TB agents, we carried out 
a screening of a large group of novel purine conjugates with 
amino acids and short peptides. Among them, N-(purin-6-yl)
glycyl-(S)-glutamic acid ((S)-1a, Fig. 1) and N-(2-aminopu-
rin-6-yl)glycyl-(S)-glutamic acid ((S)-1b) were the most 
active and exhibited high antimycobacterial activity against 
both the standard laboratory strain (M. tuberculosis H37Rv) 
and the MDR-TB strain (Krasnov et al. 2016).
It has been found that the analogs of compounds (S)-
1a,b in which the (S)-glutamic acid fragment is replaced 
by residues of other α-amino acids, as well as the analogs 
in which the glycine fragment is replaced by residues of 
various ω-amino acids, do not exhibit substantial antimy-
cobacterial activity (Musiyak et al. 2019). The purpose of 
this work was to obtain the analogs of compounds (S)-1a,b 
containing fragments of natural α-amino acids instead of 
glycine moiety. We used the following α-amino acids as 
simple structures without any additional functional groups: 
(S)-alanine, (S)-phenylalanine (common aromatic α-amino 
acid), and (S)-valine (common branched aliphatic α-amino 
acid). Moreover, special attention was paid to monitoring the 
enantiomeric purity of the target compounds, since stereo 
configuration is known to significantly affect the biological 
activity of substances (Islam et al. 1997; Melchert and List 
2007; Lin et al. 2011).
Results and discussion
Initially, synthesis of purine conjugates containing (S)-
alanine (4a), (S)-phenylalanine (4b) or (S)-valine (4c) frag-
ments instead of glycine residue was carried out by cou-
pling of N-(purin-6-yl)-(S)-amino acids (S)-2a–c to dimethyl 
(S)-glutamate followed by alkaline hydrolysis (Scheme 1). 
The starting compounds, N-(purin-6-yl)-(S)-amino acids 
(S)-2a–c, were synthesized by the nucleophilic substitu-
tion of chlorine in 6-chloropurine with the corresponding 
Fig. 1  Structures of the parent compounds (S)-1a,b (Krasnov et  al. 
2016)
Scheme 1  Synthesis of compounds 4a–c, (R)-5 and (S)-5 
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(S)-amino acids in aqueous  Na2CO3 under reflux accord-
ing to the described procedure (Ward et al. 1961). It should 
be noted that in the original work (Ward et al. 1961) there 
was no information about enantiomeric purity of the purinyl 
amino acids obtained under rather drastic conditions. So, we 
decided to check enantiomeric purity of compounds 2a–c by 
the example of phenylalanine derivatives 2b, thereby con-
firming the absence of racemization at the stage of nucleo-
philic substitution. To do this, we converted compounds (R)-
2b and (S)-2b to methyl esters (R)-5 and (S)-5, respectively 
(Scheme 1), and then performed analysis of their enantio-
meric purity (> 99% ee) by chiral HPLC.
The coupling of N-(purin-6-yl)-(S)-amino acids (S)-2a–c 
to dimethyl (S)-glutamate was carried out in the presence of 
N,N′-dicyclohexylcarbodiimide (DCC), 1-hydroxybenzotria-
zole (HOBt), and N,N-diisopropylethylamine (DIEA). We 
were surprised to observe double sets of signals in the 1H 
and 13C NMR spectra of products 3a–c (according to 1H 
NMR, in a 6:4 ratio). It should be noted that when conduct-
ing coupling of achiral carboxy component (N-(purin-6-yl)
glycine and N-(purin-6-yl)-beta-alanine) to chiral amino 
component (methyl (S)-tyrosinate, methyl (S)-serinate, or 
dimethyl (S)-glutamate) in the presence of a DCC–HOBt 
mixture, we did not observe any racemization at the chiral 
centers of the target pyrinyl dipeptides (Musiyak et al. 2019). 
So, we can conclude that in the present case racemization 
occurs at the chiral center of the carboxy component, thus 
leading to the formation of a mixture of (S,S)- and (R,S)-
diastereomers. Varying the reaction conditions (changing 
the order of adding the reagents, loading reagents at 0 °C, 
using O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
tetrafluoroborate (TBTU) instead of DCC/HOBt mixture) 
did not affect the diastereomeric composition of the products 
3a–c. Alkaline hydrolysis of diesters 3a–c led to compounds 
4a–c, which were also mixtures of diastereomers in a 6:4 
ratio (according to 1H NMR spectroscopy).
To obtain the target conjugates 4a–c in diastereomerically 
pure form, we used an alternative approach that was based 
on the nucleophilic substitution of chlorine in 6-chloropurine 
with dipeptides (S,S)-7a–c (Scheme 2). The protected dipep-
tides (S,S)-6a–c obtained according to the known procedure 
(Deng et al. 2008) were used as the starting compounds. The 
subsequent deprotection of ester protecting groups by alka-
line hydrolysis followed by Boc-group cleavage via treat-
ment with trifluoroacetic acid led to dipeptides (S,S)-7a–c, 
their characteristics were identical to those described in the 
literature (McGregor and Carpenter 1961; Gray and Khoujah 
1969; Deng et al. 2008). The interaction of dipeptides (S,S)-
7a–c with 6-chloropurine in aqueous  Na2CO3 under reflux 
led to the products (S,S)-4a–c (Scheme 2). Diastereomeric 
purity of these compounds was confirmed by 1H and 13C 
NMR spectral data.
This approach was also applied for the synthesis of 2-ami-
nopurine derivatives, the structural analogs of compound 
(S)-1b. Interaction of dipeptides (S,S)-7a,b with 2-amino-
6-chloropurine (ACP) in aqueous  Na2CO3 under reflux 
afforded the target diastereomerically pure products (S,S)-
8a,b (Scheme 2). It has been found that part of the starting 
ACP does not react under these conditions. In the case of the 
synthesis of compound (S,S)-8a, 6% of unreacted ACP was 
isolated; taking this into account, the yield of product (S,S)-
8a was 34%. In the case of compound (S,S)-8b, significantly 
more ACP (39%) was isolated from the reaction mixture, and 
the product yield was 28%, relative to reacted ACP.
During the synthesis of conjugates (S,S)-4b,c and (S,S)-
8b, we observed unexpected intramolecular cyclization of 
dipeptides (S,S)-7b,c with the formation of diketopipera-
zines (S,S)-9b,c (Scheme 2). Because of this side process, 
the yield of target products was decreased, and their puri-
fication was rather laborious. The structure of compounds 
(S,S)-9b,c was confirmed by 1H and 13C NMR spectroscopy 
and CHN elemental microanalysis; the characteristics of 
(S)-phenylalanine derivative (S,S)-9b were identical to those 
described in the literature (Kleinsmann and Nachtsheim 
2013).
Compounds (S,S)-4a–c were used for identification of 
the diastereomers formed via the coupling of N-(purin-
6-yl)-α-amino acids (S)-2a–c to dimethyl (S)-glutamate 
Scheme 2  Synthesis of compounds (S,S)-4a–c, (S,S)-8a,b and (S,S)-3a–c 
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(Scheme 1). The diastereomerically pure dimethyl esters 
(S,S)-3a–c were obtained from conjugates (S,S)-4a–c 
(Scheme 2), which made it possible to assign correspond-
ing peaks in HPLC chromatograms of diastereomeric 
mixtures 3a–c. When comparing the HPLC and 1H, 13C 
NMR spectral data of individual diastereomers (S,S)-3a–c 
(> 99% de) with the data obtained for mixtures 3a–c, we 
found that in all cases the coupling of compounds (S)-
2a–c to dimethyl (S)-glutamate (Scheme 1) resulted in 
predominant formation of (S,S)-diastereomers; that is, 
products 3a–c were mixtures of (S,S)-and (R,S)-diastere-
omers in a 6:4 ratio. Moreover, it has been shown that 
when N-(purin-6-yl)-(R)-phenylalanine [(R)-2b] was used 
as a carboxy component, exactly the same mixture of dias-
tereomers [(S,S)-3b/(R,S)-3b 6:4] was formed as in the 
case of N-(purin-6-yl)-(S)-phenylalanine (S)-2b. Thus, the 
configuration of chiral center of the starting N-(purin-6-
yl)-α-amino acid does not affect the diastereomeric com-
position of products. So, we suppose that (S,S)- and (R,S)-
diastereomers are formed from the same chirally labile 
intermediate.
It is known that histidine (imidazole-substituted amino 
acid), which can be considered as a structural analog of 
N-(purin-6-yl)-α-amino acids, is racemized while DCC 
treatment (Scheme 3) (Jones et  al. 1980). Histidine is 
supposed to form the corresponding O-acylisourea while 
interaction with DCC. Racemization of the chiral center 
occurs with the participation of the imidazole Nπ atom that 
acts as a proton acceptor (mechanism A) or as a nucleo-
phile interacting with a carbonyl fragment (mechanism 
B). It is noted that the presence of Nτ-protecting group is 
not a hindrance for this process; at the same time, in the 
case of Nπ-protected histidine racemization does not occur.
We suppose that the racemization of the chiral center 
of N-(purin-6-yl)-α-amino acids occurs with the partici-
pation of the imidazole fragment, as in the case of histi-
dine. Therefore, we obtained N-(9-benzylpurin-6-yl)-(S)-
alanine ((S)-11a) and N-(7-deazapurin-6-yl)-(S)-alanine 
((S)-11b) by the interaction of 9-benzyl-6-chloropurine 
(10a) (Kelley et al. 1988) or the commercially available 
7-deaza-6-chloropurine (10b) with (S)-alanine in aqueous 
 Na2CO3 under reflux (Scheme 4).
It has been found that the coupling of N-(9-benzylpu-
rin-6-yl)-(S)-alanine (S)-11a to dimethyl (S)-glutamate in 
the presence of DCC, HOBt, and DIEA is accompanied by 
racemization and leads to the product 12a that is a mix-
ture of diastereomers in a 6:4 ratio (Scheme 4), as in the 
case of N9-unsubstituted analogs (Scheme 1). In the case 
of N-(7-deazapurin-6-yl)-(S)-alanine (S)-11b, racemization 
also occurred, despite the absence of the N7 atom (analog 
of Nπ atom in histidine) in the purine fragment, resulting in 
product 12b as a 6:4 mixture of diastereomers. The alkaline 
hydrolysis of compound 12b led to the product 13b as a 7:3 
mixture of diastereomers, according to the 1H NMR data 
(Scheme 4). The results obtained indicate that the imidazole 
nitrogen atoms of N-(purin-6-yl)-α-amino acids either are 
not involved in the racemization process during the coupling 
reaction in the presence of DCC at all, or do not play a key 
role in this process. In general, the question of the mecha-
nism of N-(purin-6-yl)-α-amino acid racemization requires 
further study.
To identify diastereomers in mixtures 12a and 12b, dias-
tereomerically pure conjugates (S,S)-13a,b were synthesized 
by the nucleophilic substitution of chlorine in 9-benzyl-
6-chloropurine (10a) or in 7-deaza-6-chloropurine (10b) 
with dipeptide (S,S)-7a (Scheme 5). It should be noted 
that the conversion of compound 10b was only about 50%; 
so, the yield of the product (S,S)-13b was 42% relative to 
reacted 10b. To find more efficient synthetic approach to 
(S,S)-13b, we varied the reaction conditions. Unfortunately, 
we did not observe the product formation neither in aque-
ous HCl (Liu and Robins 2007), nor while using DMF as a 
solvent (Terrier 2013), nor without any solvent (Novosjolova 
et al. 2015).
Diastereomerically pure compounds (S,S)-13a,b were 
converted to dimethyl esters (S,S)-12a,b (Scheme 5). This 
made it possible to assign corresponding peaks in HPLC 
chromatograms of diastereomeric mixtures 12a,b. When 
comparing the HPLC data (Fig. 2) and 1H, 13C NMR spec-
tra of individual diastereomers (S,S)-12a,b (> 99% de) with 
Scheme 3  Proposed mechanisms of the histidine racemization (Jones et al. 1980)
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the data of mixtures 12a,b, we found that the coupling of 
N-(9-benzylpurin-6-yl)-(S)-alanine and N-(7-deazapurin-
6-yl)-(S)-alanine (compounds (S)-11a and (S)-11b) to 
dimethyl (S)-glutamate (Scheme 5) also led to predominant 
formation of (S,S)-diastereomers as it was observed for the 
coupling reaction of N-(purin-6-yl)-(S)-amino acids ((S)-
2a–c) (Scheme 1).
The in vitro antimycobacterial activity of conjugates 
4a–c, (S,S)-4a, (S,S)-8a, and 13b against Mycobacte-
rium tuberculosis H37Rv strain was studied in the Ural 
Research Institute of Phthisiopulmonology (National 
Medical Research Center, Ministry of Healthcare of the 
Russian Federation, Ekaterinburg, Russia). The minimum 
inhibitory concentrations (MIC) of these compounds 
were determined by the previously described procedure 
(Krasnov et al. 2016). Among tested compounds, alanine 
derivative 4a was found to exhibit the highest inhibitory 
activity (MIC 3.1 μg/mL), while phenylalanine (4b) and 
valine (4c) derivatives were not significantly active (MIC 
6.2–12.5  μg/mL). Moreover, individual diastereomer 
(S,S)-4a exhibits the same antimycobacterial activity as 
the mixture 4a of (S,S)- and (R,S)-diastereomers in 6:4 
ratio (MIC 3.1 μg/mL). It has been also demonstrated that 
the modification of structure 4a by introducing an amino 
group at position C2 of the purine core ((S,S)-8a) or by 
replacement of the imidazole moiety with pyrrole frag-
ment (13b) leads to the decreased inhibitory activity (MIC 
6.2–12.5 μg/mL). In general, these results show that the 
replacement of the glycine fragment in structures (S)-1a,b 
with other α-amino acid residues leads to a decrease in 
antimycobacterial activity.
Scheme 4  Synthesis of compounds (S)-11a,b, 12a,b and 13b 
Scheme 5  Synthesis of diastereomerically pure compounds (S,S)-13a,b and (S,S)-12a,b 
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Conclusion
In summary, we developed the synthetic approaches to 
novel purine and 2-aminopurine conjugates with dipep-
tides bearing the (S)-glutamic acid terminal fragment, 
and methods for monitoring their enantiomeric and dias-
tereomeric composition. It has been shown that approach 
based on the nucleophilic substitution of chlorine in 
6-chloropurine and 2-amino-6-chloropurine with dipep-
tides is racemization-free and leads to the diastereomeri-
cally pure target products. It has been found that another 
approach based on the coupling of N-(purin-6-yl)-(S)-
amino acids to dimethyl (S)-glutamate is accompanied 
by racemization of the carboxy component chiral center 
and leads to the mixtures of (S,S)- и (R,S)-diastereomers 
in a 6:4 ratio.
To verify the hypothesis that the racemization of the 
chiral center of N-(purin-6-yl)-α-amino acids proceeds 
with the participation of the imidazole nitrogen atoms via 
the stage of formation of a chirally labile intermediate, we 
synthesized N-(purin-6-yl)-(S)-alanine analogs differing 
in the structure of the imidazole fragment: N-(9-benzyl-
purin-6-yl)-(S)-alanine and N-(7-deazapurin-6-yl)-(S)-
alanine. Since the coupling of these compounds to dime-
thyl (S)-glutamate was also accompanied by racemization; 
it can be assumed that the imidazole fragment does not 
play a crucial role in the course of this process.
Some of the obtained compounds were found to exhibit 
moderate activity against M. tuberculosis H37Rv.
Materials and methods
General
N-(Purin-6-yl)-(S)-alanine (S)-2a (Ward et al. 1961), dime-
thyl N-Boc-(S)-phenylalaninyl-(S)-glutamate (S,S)-6b (Deng 
et al. 2008) and 9-benzyl-6-chloropurine 10a (Kelley et al. 
1988) were obtained as previously described. N-(Purin-
6-yl)-α-amino acids (S)-2b,c, (R)-2b (Ward et al. 1961), 
dimethyl N-Boc-(S)-alaninyl-(S)-glutamate (S,S)-6a, and 
dimethyl N-Boc-(S)-valyl-(S)-glutamate (S,S)-6c (Deng 
et al. 2008) were synthesized by analogy with the known 
methods. Other reagents are commercially available and 
were purchased from Alfa Aesar (UK) and Sigma-Aldrich 
(Germany).
The solvents were purified according to traditional 
methods and used freshly distilled. Melting points were 
obtained on a SMP3 apparatus (Barloworld Scientific, UK). 
Optical rotations were measured on a Perkin Elmer 341 
polarimeter (Perkin Elmer, USA). The 1H NMR spectra 
were recorded on Bruker DRX-400 (400 MHz) or Bruker 
Avance 500 (500 MHz) (Bruker, Germany); the 13C NMR 
spectra were recorded on Bruker Avance 500 (125 MHz); 
TMS was used as internal reference. CHN elemental micro-
analyses were performed using Perkin Elmer 2400 II ana-
lyser (Perkin Elmer, USA). Analytical TLC was performed 
using Sorbfil plates (Imid, Russia). Flash-column chroma-
tography procedures were performed using Silica gel 40 
(230–400 mesh) (Alfa Aesar, UK). For ion exchange resin 
Fig. 2  HPLC chromatograms of compounds: a 3a,b (S,S)-3a (S,S-Whelk-O1, 0.025 N aqueous AcONa–MeOH, 55:45, 0.75 mL/min, detection 
at 280 nm); c 12b,d (S,S)-12b (S,S-Whelk-O1,  H2O–MeOH, 55:45, 0.8 mL/min, detection at 280 nm)
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purification, we used Amberlite IR-120(H) resin (Alfa Aesar, 
UK). Analytical chiral HPLC of compounds 3a, (S,S)-3a, 
12b, (S,S)-12b was performed on a Agilent 1100 instru-
ment (Agilent Technologies, USA) using a S,S-Whelk-O1 
column (250 × 4.6 mm, 5 μm) (Phenomenex, USA); ana-
lytical chiral HPLC of compounds 3b, (S,S)-3b, 3c, (S,S)-
3c, (R)-5, (S)-5, 12a, (S,S)-12a was performed on Knauer 
Smartline-1100 instrument (Knauer, Germany) using the 
following columns: Chiralcel OD-H (250 × 4.6 mm, 5 μm) 
(Daicel, Japan) for compounds 3b, (S,S)-3b, 12, (S,S)-12; 
Chiralpak AD (250 × 4.6 mm, 5 μm) (Daicel, Japan) for 
compounds 3c, (S,S)-3c, or S,S-Whelk-O1 (250 × 4.6 mm, 
5 μm) (Phenomenex, USA) for compounds (R)-5, (S)-5. Pre-
parative HPLC of compounds (S,S)-4b, (S,S)-4c, (S,S)-8b, 
(S,S)-9b was performed on a Shimadzu Prominence LC-20 
instrument (Shimadzu, Japan) using a Phenomenex Luna 
C18(2) column (250 × 21.2 mm, 5 μm) (Phenomenex, USA). 
The high-resolution mass spectra were obtained on a Bruker 
maXis Impact HD mass spectrometer (Bruker, Germany), 
electrospray ionization with direct sample inlet (4  dm3/min 
flow rate).
General procedure for the coupling reactions 
(synthesis of compounds 3a–c, 12a,b)
DIEA (345 μL, 1.98 mmol), HOBt (0.27 g, 1.98 mmol), 
and DCC (0.41 g, 1.98 mmol) were successively added to 
a suspension of compound (S)-2a–c, (R)-2b, or (S)-11a,b 
(1.98 mmol) in DMSO or DMF (10 mL) under stirring at 
room temperature. After 15 min, dimethyl (S)-glutamate 
hydrochloride (0.42 g, 1.98 mmol) was added to the reac-
tion mixture. The reaction mixture was stirred at room 
temperature for 48 h. The resulting precipitate was filtered 
off and washed with DMSO or DMF (3 × 0.5 mL), the fil-
trate and washings were poured in cold water (150 mL) and 
extracted with n-BuOH (4 × 25 mL). The combined organic 
layers were washed with 5% aqueous  NaHCO3 (3 × 20 mL), 
saturated aqueous NaCl (3 × 20 mL), then evaporated to dry-
ness under reduced pressure. In the case of (S)-11a, EtOAc 
(4 × 25 mL) was used for extraction; combined organic lay-
ers were dried over  MgSO4 before evaporation. In all cases 
the residue was purified by flash column chromatography on 
silica gel  (CHCl3–EtOH as an eluent).
General procedure for alkaline hydrolysis (synthesis 
of compounds 4a–c, 13b)
Compound 3a–c or 12b (0.500 mmol) was dissolved in 
0.5 M aqueous LiOH (3 mL, 1.50 mmol). The reaction 
mixture was stirred at room temperature for 24 h, and then 
cooled to 0 °C (ice bath); the pH was adjusted to 3 by con-
centrated HCl. In the cases of 3a,b and 12b, the resulting 
precipitate was filtered off and washed with cold water 
(3 × 0.5 mL). In the case of 3c, the resulting solution was 
treated with ion-exchange resin Amberlite IR-120(H); the 
resin was washed with water; then the target compound was 
eluted with a water–pyridine 9:1 mixture; the eluate was 
evaporated to dryness under reduced pressure.
General procedure for the synthesis of methyl 
esters (R)‑5, (S)‑5 and dimethyl esters (S,S)‑3a–c, 
(S,S)‑12a,b
SOCl2 (38 μL, 0.330  mmol (for (R)-2b, (S)-2b), 76 
μL, 0.660  mmol (for (S,S)-4b and (S,S)-13a), 101 μL, 
0.880 mmol (for (S,S)-4a,c) or 114 μL, 0.990 mmol (for 
(S,S)-13b)) was added to a suspension of compound (R)-2b, 
(S)-2b, (S,S)-4a–c or (S,S)-13a,b (0.220 mmol) in absolute 
MeOH (3 mL) under stirring at 0 °C. The reaction mixture 
was stirred at 0 °C for 30 min and then at room tempera-
ture for 24 h. The solvent was evaporated to dryness under 
reduced pressure; the residue was treated with cold  Et2O, 
and the resulting precipitate was filtered off.
General procedure for the synthesis of dipeptides 
(S,S)‑7a–c
0.5 M aqueous LiOH (40 mL, 25.1 mmol) was added to 
a solution of compound (S,S)-6a–c (8.37 mmol) in EtOH 
(10 mL) at to 0 °C. The reaction mixture was stirred at 0 °C 
for 30 min, then at room temperature for 4 h. The reaction 
mixture was washed with EtOAc (2 × 10 mL), acidified with 
4 M HCl to pH 3 and extracted with EtOAc (3 × 15 mL). 
The combined organic layers were dried over  MgSO4 and 
evaporated to dryness under reduced pressure. The residue 
was dissolved in trifluoroacetic acid (20 mL); then the reac-
tion mixture was stirred at room temperature for 1 h and 
evaporated under reduced pressure. The residue was dis-
solved in water (20 mL); the solution was alkalized with 
5% aqueous  NaHCO3 to pH 5. The resulting solution was 
treated with ion-exchange resin Amberlite IR-120(H); the 
resin was washed with water; then the target compound was 
eluted with a water–pyridine 9:1 mixture. The eluate was 
evaporated to dryness under reduced pressure.
General procedure for the nucleophilic substitution 
reactions (synthesis of compounds (S,S)‑4a–c, 
(S,S)‑8a,b, (S)‑11a,b, and (S,S)‑13a,b)
Na2CO3 (0.16 g, 1.52 mmol) and 6-chloropurine, 2-amino-
6-chloropurine or compounds 10a,b (1.02 mmol) were 
successively added to a solution of compound (S,S)-7a–c 
or (S)-alanine (2.03 mmol) in water (5 mL). The reaction 
mixture was refluxed for 4–6 h; the resulting solution was 
cooled to 0 °C and acidified with concentrated HCl to pH 
414 V. V. Musiyak et al.
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3. Further operations are described for each compound in 
Electronic supplementary material.
Analytical data for all compounds can be found in Elec-
tronic supplementary material.
Assessment of antimycobacterial activity
The inhibitory effect of compounds 4a–c, (S,S)-4a, (S,S)-
8a and 13b was studied against M. tuberculosis H37Rv 
strain. The minimal inhibitory concentration (MIC) for 
each compound was determined by the micro broth dilution 
method (Krasnov et al. 2016). All compounds tested were 
dissolved in DMSO and their 1/2 dilutions were added in 
tubes with 5 ml of the Löwenstein–Jensen medium. Each 
compound was tested at six concentrations 12.5, 6.25, 3.1, 
1.5, 0.7, and 0.35 μg/mL. Tubes with Löwenstein–Jensen 
medium (5 mL) containing tested compounds and those 
without them (controls) were inoculated with a suspension 
of M. tuberculosis H37Rv strain and incubated at 37 °C 
for 10 days. The mycobacterial growth was assessed by the 
standart procedure: the appearance of zones of mycobacte-
rial growth delay (more than 10 mm) indicated the pres-
ence of antimycobacterial properties of tested compounds 
at the studied concentrations. The value of growth retarda-
tion zone (in mm) was proportional to the antimycobacte-
rial activity of the compounds. Growth delay (100 mm or 
more) was considered as a complete mycobacteria growth 
inhibition. Isoniazid (Alfa Aesar, UK) was used as a refer-
ence drug (MIC 0.1 μg/mL).
Supplementary Information The online version contains supplemen-
tary material available at https ://doi.org/10.1007/s0072 6-021-02958 -0.
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